Iradimed (IRMD) Net Margin (2013 - 2026)

Iradimed (IRMD) has reported Net Margin for 14 consecutive years, with 25.5% the latest figure, recorded in Q2 2026.

• On a quarterly basis, Net Margin fell 280.0% year-over-year to 25.5% in Q2 2026; TTM through Jun 2026 was 26.62%, a 91.0% increase from a year earlier, with the FY2025 full-year figure at 26.73%, up 142.0% from the prior year.
• Net Margin was 25.5% for Q2 2026 at Iradimed, down from 26.47% in the prior quarter.
• Over five years, Net Margin peaked at 30.7% in Q3 2023 and troughed at 17.86% in Q4 2023.
• A 5-year average of 25.13% and a median of 25.53% in 2022 frame the typical range for Net Margin.
• The widest YoY moves for Net Margin: up 1050 bps in 2022, down 807 bps in 2022.
• Over 5 years, Net Margin stood at 24.72% in 2022, then slipped by 28 bps to 17.86% in 2023, then rose by 28 bps to 22.94% in 2024, then rose by 22 bps to 28.06% in 2025, then retreated by 9 bps to 25.5% in 2026.
• The last three Net Margin figures came in at 25.5% (Q2 2026), 26.47% (Q1 2026), and 28.06% (Q4 2025), per Business Quant data.